医学
托珠单抗
安慰剂
内科学
阿纳基纳
临床终点
炎症
C反应蛋白
随机化
免疫学
胃肠病学
随机对照试验
疾病
病理
替代医学
作者
Nicholas Funderburg,Carey L. Shive,Zhengyi Chen,Curtis Tatsuoka,Emily Bowman,Chris T. Longenecker,Grace A. McComsey,Brian Clagett,Dominic Dorazio,Michael L. Freeman,Scott F. Sieg,Daniela Moisi,Donald D. Anthony,Jeffrey M. Jacobson,Sharon L. Stein,Leonard H. Calabrese,Alan Landay,Charles Flexner,Keith W. Crawford,Edmund V. Capparelli,Benigno Rodriguez,Michael M. Lederman
摘要
Abstract Background People with human immunodeficiency virus (PWH) are at increased risk for comorbidities, and plasma interleukin 6 (IL-6) levels are among the most robust predictors of these outcomes. Tocilizumab (TCZ) blocks the receptor for IL-6, inhibiting functions of this cytokine. Methods This was a 40-week, placebo-controlled, crossover trial (NCT02049437) where PWH on stable antiretroviral therapy (ART) were randomized to receive 3 monthly doses of TCZ or matching placebo intravenously. Following a 10-week treatment period and a 12-week washout, participants were switched to the opposite treatment. The primary endpoints were safety and posttreatment levels of C-reactive protein (CRP) and CD4+ T-cell cycling. Secondary endpoints included changes in inflammatory indices and lipid levels. Results There were 9 treatment-related toxicities of grade 2 or greater during TCZ administration (mostly neutropenia) and 2 during placebo administration. Thirty-one of 34 participants completed the study and were included in a modified intent-to-treat analysis. TCZ reduced levels of CRP (median decrease, 1819.9 ng/mL, P < .0001; effect size, 0.87) and reduced inflammatory markers in PWH, including D-dimer, soluble CD14, and tumor necrosis factor receptors. T-cell cycling tended to decrease in all maturation subsets after TCZ administration, but was only significant among naive CD4 T cells. Lipid levels, including lipid classes that have been related to cardiovascular disease risk, increased during TCZ treatment. Conclusions TCZ is safe and decreases inflammation in PWH; IL-6 is a key driver of the inflammatory environment that predicts morbidity and mortality in ART-treated PWH. The clinical significance of lipid elevations during TCZ treatment requires further study. Clinical Trials Registration. NCT02049437.
科研通智能强力驱动
Strongly Powered by AbleSci AI